THE USE OF ROMIPLOSTIM IN AN INFANT

Case report: Immune thrombocytopenia (ITP) is the most common platelet disorder in children, peaking between the ages of 1-7.The first line therapy consists of intravenous immunoglobulin, anti-D immunoglobulin or corticosteroids. Second-line treatment options are immunosuppressive therapy, Rituximab...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fatma Burçin KURTİPEK, Turan BAYHAN, Vildan ÇULHA, Neşe YARALI
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/e532f33be60f441e91ddee70a06808f3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e532f33be60f441e91ddee70a06808f3
record_format	dspace
spelling	oai:doaj.org-article:e532f33be60f441e91ddee70a06808f32021-11-10T04:38:18ZTHE USE OF ROMIPLOSTIM IN AN INFANT2531-137910.1016/j.htct.2021.10.1072https://doaj.org/article/e532f33be60f441e91ddee70a06808f32021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921012190https://doaj.org/toc/2531-1379Case report: Immune thrombocytopenia (ITP) is the most common platelet disorder in children, peaking between the ages of 1-7.The first line therapy consists of intravenous immunoglobulin, anti-D immunoglobulin or corticosteroids. Second-line treatment options are immunosuppressive therapy, Rituximab.Thrombopoietin receptor agonists are used, which increase platelet production in the bone marrow. Our case report on a child with refractory chronic ITP, who failed the first and second line therapy.Fatma Burçin KURTİPEKTuran BAYHANVildan ÇULHANeşe YARALIElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S56-S57 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Fatma Burçin KURTİPEK Turan BAYHAN Vildan ÇULHA Neşe YARALI THE USE OF ROMIPLOSTIM IN AN INFANT
description	Case report: Immune thrombocytopenia (ITP) is the most common platelet disorder in children, peaking between the ages of 1-7.The first line therapy consists of intravenous immunoglobulin, anti-D immunoglobulin or corticosteroids. Second-line treatment options are immunosuppressive therapy, Rituximab.Thrombopoietin receptor agonists are used, which increase platelet production in the bone marrow. Our case report on a child with refractory chronic ITP, who failed the first and second line therapy.
format	article
author	Fatma Burçin KURTİPEK Turan BAYHAN Vildan ÇULHA Neşe YARALI
author_facet	Fatma Burçin KURTİPEK Turan BAYHAN Vildan ÇULHA Neşe YARALI
author_sort	Fatma Burçin KURTİPEK
title	THE USE OF ROMIPLOSTIM IN AN INFANT
title_short	THE USE OF ROMIPLOSTIM IN AN INFANT
title_full	THE USE OF ROMIPLOSTIM IN AN INFANT
title_fullStr	THE USE OF ROMIPLOSTIM IN AN INFANT
title_full_unstemmed	THE USE OF ROMIPLOSTIM IN AN INFANT
title_sort	use of romiplostim in an infant
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/e532f33be60f441e91ddee70a06808f3
work_keys_str_mv	AT fatmaburcinkurtipek theuseofromiplostiminaninfant AT turanbayhan theuseofromiplostiminaninfant AT vildanculha theuseofromiplostiminaninfant AT neseyarali theuseofromiplostiminaninfant AT fatmaburcinkurtipek useofromiplostiminaninfant AT turanbayhan useofromiplostiminaninfant AT vildanculha useofromiplostiminaninfant AT neseyarali useofromiplostiminaninfant
_version_	1718440608288210944

THE USE OF ROMIPLOSTIM IN AN INFANT

Ejemplares similares